Recent Posts in ‘Pharmaceuticals and Biotech’
« Older EntriesBiotech & Pharmaceutical Patenting
May 21st, 2012
in Pharmaceuticals / Biotech / Life Sciences, Pharmaceuticals and Biotech |
In a rapidly shifting legal environment for the pharma industry, it has become crucial that biotech companies seek the most practical and competitive strategies for obtaining, extending and protecting their patent portfolios.
The 2012 London Biotech & Pharmaceuticals Patenting forum will focus on latest legal developments affecting biotech companies, with a particular focus on successful techniques and strategies for drafting and filing patent applications in multiple jurisdictions. The event will provide a unique opportunity for you to network with your fellow industry peers, key industry regulators and expert patent attorneys from across globe, allowing you to develop your current biotech practices and remain competitive in today’s rapidly changing market.
C5’s 23rd Forum on Biotech & Pharmaceuticals Patenting brings together experienced in-house counsel from both innovator and generic pharma and biotech companies and their expert legal advisors from various jurisdictions across the globe. Based on their personal experience, the expert panel will lead you through invaluable, practical, and in-depth sessions on:
- The latest case law developments regarding SPCs and the impact on the industry
- The patentability of diagnostic methods and the implications of the Prometheuscase in the US
- A comparison of the approaches in the EU member states on research exemptions in clinical trials
- The use of patent litigation insurance cover to enable smaller life science developers to protect their IP
- The latest strategies and priorities of the EPO
- A comparison of the approaches to inventiveness in different member states in the EU
- Procedural developments in Europe, including developments in evidence collection proceedings
- Analysing the US Biosimilars Framework and developments in the EU
- An update on case law in key jurisdictions including the US, UK, Germany, France and Switzerland
Tags: c5, C5 Publications, Legal, legal conferences, Legal Events, pharma
No Comments »
Freedom to Operate
April 5th, 2012
in Pharmaceuticals / Biotech / Life Sciences, Pharmaceuticals and Biotech |
I wanted you to know that based on industry feedback from fellow patent experts we are happy to announce – for your review and early registration – the topics and speaker faculty for our 9th International Forum on Freedom to Operate, which will take place on the 9th and 10th May in Frankfurt, Germany.
This practical forum on the latest strategies for cost-effective, high value and low risk FTO assessments gathers numerous eminent in-house experts from the pharma, biotech and chemical industries. Based on their first-hand experience, the distinguished panel will share their extensive insights and discuss the latest legal and regulatory developments for successful FTO opinion writing.
http://www.c5-online.com/fto
C5’s FTO forum is the only event in Europe specifically designed for IP and Information Science experts involved with FTO practices in pharma, biotech and chemical sectors. In particular learn how to overcome the biggest challenges facing Freedom to Operate (FTO) searches, analysis and opinion writing today and cut through the complexities of:
- Current EPO, US and European National case lawon claim interpretation and validity
- Conducting FTO searches more time efficiently and cost effectively
- Hear best practice approaches to good search strategy by leading in-house experts
- Explore new technology tools and trends
- Assess search strategies for different sized projects
- New developments on SPCs and paediatric exclusivity and how they could threaten your patent strategy
- Stratifying and quantifying FTO risks: how to deal with the grey areas
- Downstream effects of EPO divisional applications and the America Invents Act on your FTO strategy
- New considerations for FTO practice arising from recent gene patenting decisions (Lilly v HGS and Brüstle v Greenpeace)
- Addressing FTO challenges in emerging markets:China, India, Brazil
For more information, check the link below:
http://www.c5-online.com/files/pdf/marketing/511L12-FRA-E.pdf
Tags: c5, pharma
No Comments »
Pharma Patent Lifecycles
April 2nd, 2012
in Legal, Legal Conferences, Legal Conferences, Pharmaceuticals / Biotech / Life Sciences, Pharmaceuticals and Biotech |
The pharmaceutical industry stands on the edge of a patent cliff, with many blockbuster drugs going off patent in 2012 and 2013.
This decline in the number of patents not only creates problems for big pharma innovators, but also puts generic companies under pressure to maximise their opportunities. With the cost of research and development continually rising and the need to obtain maximum revenue from existing patent terms, patent lifecycle management is becoming more crucial for the pharma industry than ever before.
At this time it is essential that you know how to modify your lifecycle strategy to legitimately extend revenue streams and take advantage of the changing patent landscape.
Benchmark your strategies for patent lifecycle extensions with your direct peers and gain an advantage over your competitors.
For more information, check the link below:
http://www.c5-online.com/files/pdf/marketing/509L12-LON-E.pdf
Tags: c5, Legal, Legal conference, legal conferences, patent law, pharma
No Comments »
Pharma Patent Lifecycles
March 21st, 2012
in Healthcare, Pharmaceuticals and Biotech |
By attending this well-recognised industry event you will be able to:
Benchmark your strategies for patent lifecycle extensions with your direct peers in leading pharma and biotech companies and gain advantage over your competitors.
The eminent speakers will share their best practice insights and offer clarity on the latest SPC court decisions and regulatory developments and the implications for your patent lifecycle management strategies.
In addition you will gain a full analysis of the complex issues and case law surrounding the intersection of competition law and IP, with a particular focus on reverse settlements, ‘abuse of dominance’, disclosure of prior art and patent pooling. You will receive direct guidance from the European Commission on lifecycle extensions and how to avoid anti-trust enforcement action.
Our outstanding speaker faculty includesexpert in-house counsel:
- Tony Rollins, Managing Counsel European Patents,Merck (UK)
- Jürgen Dressel, Head of Patent Litigation ex USA,Novartis (Switzerland)
- Brian Tempest, Chairman,Hale & Tempest (Ex CEO Ranbaxy)
- James Robertson, Senior Manager, Patent Counsel,GlaxoSmithKline (Belgium)
- Lars Sparre Conrad, Senior Patent Counsel, Corporate Patents & Trademarks,H. Lundbeck (Denmark)
- Dr. Deepak Murpani, Vice President, R&D (Formulation/Product development), Genepharm (Greece)
- Bernard McDonald, Global IP Manager, Legal Affairs Group,Emergent BioSolutions (UK)
Plushear directly from the regulator and patent offices about the latest case law decisions and their interpretations:
- Dieter Tzschoppe, Director Pure and Applied Organic Chemistry,European Patent Office
- Lavinia Teodorescu, DG Competition Antitrust Pharma and Health Services, European Commission
- Martijn de Lange,Netherlands Patent Office
- Dr Lawrence Cullen, Deputy Director (Biotechnology, Pharmaceuticals & Organic Chemistry) Patents Directorate,Intellectual Property Office (UK IPO)
And meet many more international IP expert speakers.
For more information, check the link below:
http://www.c5-online.com/files/pdf/marketing/509L12-LON-E.pdf
Tags: c5, pharma
No Comments »
Paragraph IV Disputes
March 12th, 2012
in Legal Conferences, Legal Conferences, Pharmaceuticals / Biotech / Life Sciences, Pharmaceuticals and Biotech |
Brand name and generic pharmaceutical companies are beginning to feel the initial impact of the patent cliff:
the pecuniary perils of patent loss and the economic consequences associated with the decline of Hatch-Waxman market exclusivity. As a result, the industry has entered an era of “extreme” Paragraph IV litigation where the monetary ante has never been higher.
To help you respond to the challenges of this new era, ACI’s 6th Annual Paragraph IV Disputes conference will guarantee your access to the leading legal minds in this area. A “who’s who” of Hatch-Waxman litigators — for both brand names and generics — will help you conquer the patent crisis of 2012 by addressing such industry shaping topics as:
- The impact of the AIA on Hatch –Waxman litigation
- Carve-outs, use codes and labeling
- Claim construction
- Prior art obviousness and obvious-type double patenting
- Inducement of infringement and divided infringement
- Inequitable conduct
- Damages
Hear also from renowned federal jurists and a key official from the Federal Trade Commission. Learn firsthand how the bench analyzes the theories of your case and what the FTC deems as “fair and foul” in the settlement of pharmaceutical patent disputes.
Complete your professional training by attending one or more of thesecustomized Working Groups, Workshops and Master Classes:
Hatch-Waxman and BPCIA 101 — A Primer on IP Basics and Regulatory Fundamentals which will provide the patent and regulatory backdrop for the more in-depth Hatch-Waxman litigation controversies discussed in the main conference;
A Working Group Session on Assessing The Impact of New PTO Procedures Under the AIA on Paragraph IV Litigation which will address how new pre- and post issuance procedures may alter certain components of Paragraph IV litigation and parallel proceedings between the Federal Courts and PTO; and
The Master Class on Settling Paragraph IV Disputes: Drafting and Negotiating Strategies for Brand-Names and Generics which will give practical and hands-on strategies for drafting and negotiating settlement agreements that will pass muster with the FTC.
Tags: c5, legal conferences, Legal Events, pharma
No Comments »
Biotech Patenting
March 6th, 2012
in Legal, Legal Conferences, Legal Conferences, Litigation, Pharmaceuticals / Biotech / Life Sciences, Pharmaceuticals and Biotech |
Our 22nd Biotech Patenting forum will bring together key regulators from Germany, Spain, the EPO and USPTO, leading in-house representatives from GSK, Bayer, Pfizer, Merck, UCB, Ipsen Pharma, Qiagen, GE Healthcare (and many more) and their legal advisers from different European jurisdictions and the US.
This outstanding expert panel will provide you with up-to-the-minute information on the latest case law in Europe and the US to make sure you have the best patent strategy in place to deal with new and emerging challenges in biotech patent practice.
And our timely focus day on the US patent reform and its implications for European life sciences companies will highlight what you need to consider when enforcing and protecting your IP rights in the US.
You will hear directly from your industry peers on best practice approaches and their first hand experiences with current industry challenges regarding the entire patenting process throughout the patent cycle, from obtaining, extending to protecting. Issues addressed will include:
• G2/10 decision: analysing its impact on the biotech disclaimer practice across Europe
• Cross-border litigation: developing successful strategies
• Case law developments in double patenting: from a European and US perspective
• New patenting and marketing strategies to overcome the challenges of filing your SPC applications at an earlier stage
• Latest decision on patentability of stem cells: to help you examine the outcome of the CJEU decision in Brüstle
• Patentability of gene sequence patents: evaluate recent Eli Lilly v HSG decision and latest developments in the US regarding the Myriad, Prometheus and Classen cases
• US Patent Law reform: discussing the impact of the America Invests Act on European biotech firms
For more information, check the link below:
http://www.c5-online.com/files/pdf/marketing/660L12-MUN-E.pdf
Tags: c5, Legal, Legal conference, legal conferences, Legal Events
No Comments »
Biotech Patenting
March 2nd, 2012
in Legal, Legal Conferences, Legal Conferences, Pharmaceuticals and Biotech |
Our 22nd Biotech Patenting forum will bring together key regulators from Germany, Spain, the EPO and USPTO, leading in-house representatives from GSK, Bayer, Pfizer, Merck, UCB, Ipsen Pharma, Qiagen, GE Healthcare (and many more) and their legal advisers from different European jurisdictions and the US.
This outstanding expert panel will provide you with up-to-the-minute information on the latest case law in Europe and the US to make sure you have the best patent strategy in place to deal with new and emerging challenges in biotech patent practice.
And our timely focus day on the US patent reform and its implications for European life sciences companies will highlight what you need to consider when enforcing and protecting your IP rights in the US.
Hear directly from your industry peers on best practice approaches and their first hand experiences with current industry challenges regarding the entire patenting process throughout the patent cycle, from obtaining, extending to protecting. Issues to be addressed:
G2/10 decision: analysing its impact on the biotech disclaimer practice across Europe
Cross-border litigation: developing successful strategies
Case law developments in double patenting: from a European and US perspective
New patenting and marketing strategies to overcome the challenges of filing your SPC applications at an earlier stage
Latest decision on patentability of stem cells: to help you examine the outcome of the CJEU decision in Brüstle
Patentability of gene sequence patents: evaluate recent Eli Lilly v HSG decision and latest developments in the US regarding the Myriad, Prometheus and Classen cases
US Patent Law reform: discussing the impact of the America Invests Act on European biotech firms
Tags: c5, Legal, Legal conference, legal conferences, Legal Events, pharma
No Comments »
Freedom to Operate
February 29th, 2012
in Legal, Legal Conferences, Pharmaceuticals and Biotech |
This practical forum on the latest strategies for cost-effective, high value and low risk FTO assessments gathers numerous eminent in-house experts from the pharma, biotech and chemical industries. Based on their first-hand experience, the distinguished panel will share their extensive insights and discuss the latest legal and regulatory developments for successful FTO opinion writing.
- Current EPO, US and European National case law on claim interpretation and validity
- Conducting FTO searches more time efficiently and cost effectively
- Hear best practice approaches to good search strategy by leading in-house experts
- Explore new technology tools and trends
- Assess search strategies for different sized projects - New developments on SPCs and paediatric exclusivity and how they could threaten your patent strategy
- Stratifying and quantifying FTO risks: how to deal with the grey areas
- Downstream effects of EPO divisional applications and the America Invents Act on your FTO strategy
- New considerations for FTO practice arising from recent gene patenting decisions (Lilly v HGS and Brüstle v Greenpeace)
- Addressing FTO challenges in emerging markets: China, India, Brazil
Tags: c5, legal conferences, Legal Events
No Comments »
Pharma Patent Lifecycles
February 15th, 2012
in Legal, Legal Conferences, Legal Conferences, Pharmaceuticals / Biotech / Life Sciences, Pharmaceuticals and Biotech |
Patent life cycle management is becoming more crucial for pharmaceutical companies with the cost of research and drugs continually rising and companies constantly trying to obtain the maximum financial benefit from existing patent terms. In addition to protecting existing IP rights and seeking methods to extend current patent lifecycles, pharmaceutical companies are faced with the challenge of inventing new drugs and diversifying portfolios to replace sales on older and generic drugs.
The 2012 Pharma Patent Lifecycles Forum will focus on recent cases across Europe and the US and their impact on the latest regulatory developments and strategies for patent lifecycle extensions. Our outstanding panel of experts will provide you with practical guidance on the most effective ways to successfully apply for patent term extensions and overcome the strategic challenges when dealing with the various patent offices and regulatory authorities. In addition, key regional experts will examine the current legal and regulatory processes and procedures to extend patent lifecycles in the BRIC countries, providing you with the information you need to maximise the scope of your patent portfolio.
C5’s 11th Annual Forum on Pharma Patent Lifecycles brings together eminent in-house counsel from the world’s largest pharma and biotech companies and their expert advisors from a range of jurisdictions, including the US, Europe and Asia.
Be where your industry will be on 20th and 21st June 2012 and don’t miss out on this unique opportunity to hear from and network with prominent judicial authorities, regulatory experts and industry specialists.
Tags: c5, legal conferences, Legal Events, Litigation, pharma
No Comments »
Biotech Patenting
January 30th, 2012
in Legal, Legal Conferences, Pharmaceuticals and Biotech |
In a rapidly shifting legal environment for the pharma industry, it has become crucial that biotech companies seek the most practical and competitive strategies for obtaining, extending and protecting their patent portfolios. The 2012 Munich Biotech Patenting forum will focus on latest legal developments affecting biotech companies, with a particular focus on successful techniques and strategies for drafting and filing patent applications in multiple jurisdictions. The event will provide a unique opportunity for you to network with your fellow industry peers, key industry regulators and expert patent attorneys from across globe, allowing you to develop your current biotech practices and remain competitive in today’s ever-changing and ever-expanding market.
C5’s 22nd Forum on Biotech Patenting brings together experienced in-house counsel from both innovator and generic pharma and biotech companies and their expert legal advisors from various jurisdictions across the globe. Based on their personal experience, the expert panel will lead you through invaluable, practical, and in-depth sessions on:
- Determining How the G2/10 Decision will Change Biotech Disclaimer Practice Across Europe
- Adopting New Patenting and Marketing Strategies to Overcome the Challenges of Filing your SPC Applications at an Earlier Stage
- Navigating Around the Patentability of Stem Cells Through Strategic Claim Drafting
- Case law developments in double patenting: from an European and US perspective
- Current Developments on Biotech Products and Patent Considerations for Bio-Deposits
- Successful strategies for cross-border litigation
- Managing Patents for Biosimilar Products and Understanding the Bolar Provisions in Europe
- Tackling Diagnostic Methods and Personalised Medicines
- Patentability of Gene Sequence Patents in Europe and the US
Plus maximise your time by attending the post-conference workshop on the 16th March:
Strategies for Claiming Commercial Products in your Biotech Patent Applications
Illustrating what the examiners are looking for by using examples of best practice approaches
ALSO new this year is our Focus Day on the 13 March 2012 in Munich:
US Patent Reform for European Life Science companies
Analyzing the impact of the America Invents Act on IP Owners in the Life Science Industry in Europe
This focused event will discuss the impact of the significant changes to the US patent system on life science companies and what they need to consider when enforcing and protecting their rights in the USA.
US and European legal and regulatory experts from and for the pharma and biotech industry will gather at this unique forum to provide an in-depth analysis of the regal, regulatory and business challenges and discuss the changes surrounding the America Invests Act and its impact on the life sciences industry.
Register to attend this practical focus day on the impact of the US patent reform on Tuesday, 13 March 2012 to ensure you are staying ahead of the game when enforcing and protecting your IP rights in the USA.
C5’s Biotech Patenting conference is the ONE place biotech patent practitioners come to learn and discuss the most recent and vital changes facing the industry today. Join us at the 22nd C5 Forum on Biotech Patenting for an unparalleled learning and networking opportunity!
Tags: c5, legal conferences, Legal Events
No Comments »
